Bio-Rad Laboratories Q2 Adj EPS $3.00 Beats $2.55 Estimate, Sales $681.10M Miss $687.88M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories reported Q2 adjusted earnings of $3.00 per share, beating the analyst consensus estimate of $2.55 by 17.65%. However, the company's quarterly sales of $681.10 million missed the analyst consensus estimate of $687.88 million by 0.99%, marking a 1.45% decrease from the same period last year.
August 04, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bio-Rad Laboratories' Q2 earnings beat estimates but sales missed, indicating mixed financial performance.
Bio-Rad Laboratories reported better than expected Q2 earnings but missed on sales. This mixed financial performance could lead to neutral short-term price movement for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100